CD19 and chronic myelogenous leukemia, BCR-ABL1 positive: CD19-CAR T cells showed a potent activity against RUNX1mut BP-CML blasts in patients expressing CD19 including one lymphoid-BP (mut1) and one myeloid-BP patient (mut2) with aberrant CD19 expression on 25% of blasts.